Neurocrine Biosciences
NBIX
Performance
About Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for neurological, neuroendocrine, and neuropsychiatric disorders. With a heritage of scientific founders, the company emphasizes long-term research and clinical development to address significant unmet medical needs and rare diseases. Its work spans early discovery through clinical studies, aiming to bring safe and effective medicines to patients worldwide. Headquartered in the United States, Neurocrine emphasizes brave science and patient-centered outcomes across its therapeutic areas.
Recent News
Neurocrine Biosciences Inc (NBIX) Q1 2026 Earnings Call Transcript
Neurocrine Biosciences Completes $2.9 Billion Soleno Acquisition
Neurocrine to Acquire Soleno for $2.9 B, Paying $53 per Share in Cash
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
Jupiter Neurosciences Inc (JUNS) Q4 2025 Earnings Call Transcript
Under FDA Clinical Hold, Aardvark Therapeutics Seeks Path Forward for Metabolic Drug
ASX Set to Retreat, Wall Street Loses Steam After Trump’s Threat to ‘Take Out’ Iran; Oil Rises
STAT+: Stealth Biotech Stipple Bets on Secretive ADCs
Neurocrine to Acquire Soleno Therapeutics for $2.9 Billion in Cash
Top Biotech Deals in April 2026
Trump’s New Pharmaceutical Tariffs Will Hit Small Drugmakers Hardest
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash
MGNX Restarts LINNET Gene‑Therapy Trial as GSK Wins China Nod and NBIX Acquires SLNO